J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.
Julie M. Vose,A N Pandite,R A Beveridge,R. B. Geller,M W Schuster,J. E. Anderson,C F LeMaistre,T Ahmed,A Granena,A. Keating,J M Fernandez Ranada,Patrick J. Stiff,I Tabbara,W Longo,E A Copelan,C Nichols,A Smith,D L Topolsky,P. J. Bierman,M. E. Lebsack,M Lange,L. Garrison +21 more
TL;DR: There was a trend toward a slight improvement in neutrophil engraftment post-ABMT with the PIXY321 administer by an SC route compared with GM-CSF administered by an IV route, but no differences could be identified between the two agents with respect to the time to platelet transfusion independence.
Journal ArticleDOI
Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory aggressive non-Hodgkin lymphoma
Peter H. Wiernik,Izidore S. Lossos,Joseph Tuscano,Glen Justice,Julie M. Vose,Dennis Pietronigro,Kenichi Takeshita,Annette Ervin-Haynes,Jerome B. Zeldis,Thomas M. Habermann +9 more
TL;DR: This study was designed to assess the safety and efficacy of lenalidomide in patients with relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL), and response and progression were evaluated using the IWLRC methodology.
Journal ArticleDOI
A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20+ Indolent NHL: Correlation Between Clinical Responses and AUC Pharmacokinetics.
Jonathan W. Friedberg,Julie M. Vose,Brad S. Kahl,Mark Brunvand,Andre Goy,Yvette L. Kasamon,Bart Burington,Jing Li,William Ho,Bruce D. Cheson +9 more
TL;DR: Analysis of PK data demonstrated a correlation between higher normalized drug exposure (normalized AUC) and both tumor shrinkage and clinical response, consistent with the hypothesis that rapid drug clearance (e.g. by tumor in excess of drug) may result in decreased clinical efficacy.
Journal ArticleDOI
Establishing an institutional model for the administration of tositumomab and iodine I 131 tositumomab.
TL;DR: In this article, an institutional model has been developed that ensures the efficient and safe delivery of tositumomab and iodine I 131 tositumaomab (Bexxar; Corixa Corp, South San Francisco, CA and GlaxoSmithKline, Philadelphia, PA).
Journal Article
Nccn preliminary non-hodgkin's lymphoma practice guidelines
Margaret A. Shipp,Richard F. Ambinder,Frederick R. Appelbaum,Fernando Cabanillas,N. J. Harris,G. P. Herzig,Richard T. Hoppe,Sandra J. Horning,R. D. Pezner,Maria A Rodriguez,Julie M. Vose,Joachim Yahalom,Andrew D. Zelenetz +12 more